PTO/SB/21 (09-06) 614

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Re	eduction Act of 1995, n	o.s <u>no persons are required to respond to a c</u>			U.S. DEPARTMENT OF COMMERCE displays a valid OMB control number.	
		Application Number	10/580,443			
OVP E TRANSMITTAL FORM		Filing Date	May 23, 200	May 23, 2006		
		First Named Inventor	Joachim Mo	Joachim Moormann		
2007	,	Art Unit	1614			
FEB 2 1 2007 (to be used for Myorresp	ondence after initial fili	Examiner Name				
Total Number Consension	This Submission	Attorney Docket Number	RO4245US	(#9056	8)	
Total Number of Pages in	This Submission		10 12 10 00	(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	<u></u>	
ENCLOSURES (Check all that apply) After Allowance Communication to TC						
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53		Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocat Change of Correspondence Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on C	Address X prio post	Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below): prior art references and return postcard receipt		
		URE OF APPLICANT, ATT	ORNEY OR A	GENT.		
Firm Name						
	D. Peter Hochberg Co., L.P.A.					
Signature						
Printed name D. Peter Hochberg						
	Helman	1/ \7	Reg. No. 24,6	.03		
	Her man	16,2007	27,0			
CERTIFICATE OF TRANSMISSION/MAILING						
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:						
Signature	Suller	Viv				
Typed or printed name Sean Mell		o			02/16/2007	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

CERTIFICATE OF MAILING

I hereby certify that this document is being deposited with the United States Postal Service as First Class mail in an envelope addressed: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date

noted below:

Ju Muu-

FEB 2 1 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

Joachim Moormann, et al.

Serial No.

10/580,443

Filing Date

May 23, 2006

Examiner

:

Group Art Unit

1614

Title

USE OF DEOXYPEGANINE FOR TREATING

SCHIZOPHRENIC PSYCHOSES

Attorney File

RO4245US (#90568)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 CFR 1.97

Mail Stop Amendment Commissioner for Patents P O Box 1450 Alexandria, Virginia, 22313-1450

Dear Sir,

Under the provision of 37 C.F.R. 1.56, 1.97 and 1.98, Applicant would like to call the Examiner's attention to the references listed on the attached Form PTO-1449 which are originally set forth in specification of the present application and which were noted in the Supplemental Information Disclosure Statement filed on January 30, 2007. Copies of these two references had not been provided earlier, but are now provided herewith. An English translation of the Bovin, et al. reference is also provided.

In accordance with 37 C.R.F. 1.97(b)(1), and as this Information Disclosure

Statement is being prior to the issuance of a first action on the merits of the application, no additional fee or statement is required.

In accordance with 37 C.F.R. 1.97(g) and 37C.F.R.1.97(h), filing of this Information disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 34 C.F.R. 1.56(b).

The Examiner is requested to make the attached references of record and to consider these references along with such other references deemed pertinent as a result of the Examiner's own independent search and examination.

Respectfully submitted,

Date: Gellung 16, 2007

D. Peter Hochberg Co., L.P.A. 1940 E.6th Street – 6th Floor Cleveland, OH 44114 (216) 771-3800 DPH/SM D. Peter Hochberg

Reg. No. 24,603

FORM PTO-1449

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Joachim Moormann, et al.

10/580,443

Filing Date

May 23, 2006

Examiner

Group Art Unit

1614

Date

Title

USE OF DEOXYPEGANINE FOR TREATING

SCHIZOPHRENIC PSYCHOSES

Attorney File

RO4245US (#90568)

Mail Stop Amendment Commissioner for Patents P O Box 1450

Alexandria, Virginia, 22313-1450

U S PATENT DOCUMENTS

Examiner

Document

Initial

Number

Name

U.S. Published Applications

Examiner

Document

Initial

Number

Date

Name

Foreign Patent Documents

Examiner Initial

Document

Number

Date

Country

Translation

(Yes/No)

Other Prior Art (Inc. Author, Title, Date, Pertinent Pages, Etc)

Examiner	
Initial	Document
	Bovin, R.Y., et al.; "Correction of Akinetic-Abulic Syndrome in Schizophrenics Using Cholinotropic Drugs;" Zurnal Nevropatalogii I Psihiatrii Imeni S.S. Korsakova, Izdatel' Stvo Meditsina; Moscow, Russia; Vol. 91, No. 2 (Feb. 1991), pages 111-115
	Drug Des. Disc. 14, 1-14 (1996)
Examiner	Date Considered:
/Renee Claytor/	08/10/2009 /RC/
Examiner: Initial	if reference considered, whether or not citation is in conformance with

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

considered.

Applicant

MPEP 609; Draw line through citation if not in conformance and not

Include copy of this form with next communication to